efficacy and safety of 0.5 mg fingolimod in patients with primary progressive multiple sclerosis
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
What it measured
Main measures
Long-term safety, tolerability, and efficacy.
Safety
Other measures (1)
none
Who could take part
Progressive MS
Inclusion: Patients eligible for inclusion in this study have to fulfill all of the following criteria: Exclusion: 1. Active chronic disease (or stable but treated with immune therapy) of the immune system other than MS (e.g., rheumatoid arthritis,
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the long-term safety, tolerability, and efficacy (as measured by clinical and MRI parameters of disease activity) of fingolimod 0.5 mg/day in PPMS patients.
Loading reviews and guidelines…
Related trials
- GR-2021-12373041
Phase 4 · Recruiting
Still running
- Exploring the effect of a novel therapy on intrathecal inflammation in patients with MS
Phase 4 · Moved to EU CTIS registry
- ITASIA
Completed
No result found
- SIPO20
Phase 4 · Recruiting
Still running
- SWISSMASIA
Stopped early
Stopped early
- Study to Assess the Efficacy of Mayzent on Microglia in S…
Phase 2 / Phase 3 · Stopped early
Stopped early
History
Started
Oct 2012
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error